|
|
Prepublished online as a Blood First Edition Paper on October 10, 2002; DOI 10.1182/blood-2002-05-1474.
 Previous Article | Table of Contents | Next Article 
Blood, 15 February 2003, Vol. 101, No. 4, pp. 1277-1283
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Brief report
M0 AML, clinical and biologic features of the disease, including
AML1 gene mutations: a report of 59 cases by the Groupe
Français d'Hématologie Cellulaire (GFHC) and the Groupe
Français de Cytogénétique Hématologique (GFCH)
Christophe Roumier,
Virginie Eclache,
Michelle Imbert,
Frederic Davi,
Elizabeth MacIntyre,
Richard Garand,
Pascaline Talmant,
Pascale Lepelley,
Jean Luc Lai,
Olivier Casasnovas,
Marc Maynadie,
Francine Mugneret,
Chrystele Bilhou-Naberra,
Françoise Valensi,
Isabelle Radford,
Marie Joëlle Mozziconacci,
Christine Arnoulet,
Eliane Duchayne,
Nicole Dastugue,
Pascale Cornillet,
Sylvie Daliphard,
Francine Garnache,
Najiba Boudjerra,
Helene Jouault,
Odile Fenneteau,
Béatrice Pedron,
Roland Berger,
Georges Flandrin,
Pierre Fenaux, and
Claude Preudhomme
From the Laboratoire d'Hématologie A,
Laboratoire de Cytogénétique, and Service des Maladies du
Sang, CHU Lille; Unité INSERM 524, Institut de Recherche sur le
Cancer de Lille; Laboratoire d' Hématologie, Hôpital Jean
Verdier, Bondy, Assistance Publique Hôpitaux de Paris;
Hématologie Biologique and Hématologie Clinique,
Hôpital Henri Mondor, Assistance Publique Hôpitaux de
Paris; Hématologie clinique, Hôpital Pitié
Salpetrière, Assistance Publique Hôpitaux de Paris;
Hématologie Biologique, Hôpital Necker, Assistance Publique
Hôpitaux de Paris; Laboratoire d'Hématologie and
Cytogénétique Hématologique, Institut de Biologie,
CHU Nantes; Unité d'hématologie Clinique, Service
d'hématologie biologique, and Laboratoire de
Cytogénétique, CHU Dijon; Laboratoire d'Hématologie,
CHU Bordeaux; Laboratoire de Cytogénétique Hôpital
Necker, Assistance Publique Hôpitaux de Paris; Laboratoire
d'Hématologie Moléculaire et Cytogénétique,
Institut Paoli Calmette, Marseille; Laboratoire d'hématologie
and Laboratoire de Génétique des Hémopathies,
Hôpital Purpan, Toulouse; Laboratoire d'Hématologie et de
Cytogénétique, CH Reims; Laboratoire d'Hématologie,
Etablissement de Transfusion Sanguine de Franche Comte; Service
d'Hématologie, Centre Hospitalier Alger; Hématologie
Biologique and Immunologie Biologique, Hôpital Robert Debre,
Assistance Publique Hôpitaux de Paris; Unité INSERM 301, IGM, Hôpital Saint Louis Paris, France.
Mutations of the AML1 gene are frequent
molecular abnormalities in minimally differentiated acute myeloblastic
leukemia (M0 AML), a rare type of AML. In this retrospective
multicenter study, morphologic, immunophenotypical, cytogenetic, and
molecular features of 59 de novo M0 AML cases were analyzed and
correlated to AML1 mutations. Point mutations of
AML1 gene were observed in 16 cases (27%). They were
correlated with higher white blood cell (WBC) count
(P = .001), greater marrow blast involvement
(P = .03), higher incidence of immunoglobulin H/T-cell
receptor (IgH/TCR) gene rearrangement
(P < .0001), and with a borderline significant lower
incidence of complex karyotypes. In the 59 patients, FLT3 mutations
were the only significant prognostic factors associated with short survival.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. Roudaia, M. D. Cheney, E. Manuylova, W. Chen, M. Morrow, S. Park, C.-T. Lee, P. Kaur, O. Williams, J. H. Bushweller, et al.
CBF{beta} is critical for AML1-ETO and TEL-AML1 activity
Blood,
March 26, 2009;
113(13):
3070 - 3079.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Terriou, R. Ben Abdelali, C. Roumier, L. Lhermitte, J. de Vos, P. Cornillet, O. Nibourel, K. Beldjord, H. Dombret, G. Leverger, et al.
C/EBPA methylation is common in T-ALL but not in M0 AML
Blood,
February 19, 2009;
113(8):
1864 - 1866.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. P.G. Silva, A. Lind, G. Brouwer-Mandema, P. J.M. Valk, and M. Giphart-Gassler
Trisomy 13 correlates with RUNX1 mutation and increased FLT3 expression in AML-M0 patients
Haematologica,
August 1, 2007;
92(8):
1123 - 1126.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Barbaric, T. A. Alonzo, R. B. Gerbing, S. Meshinchi, N. A. Heerema, D. R. Barnard, B. J. Lange, W. G. Woods, R. J. Arceci, and F. O. Smith
Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961
Blood,
March 15, 2007;
109(6):
2314 - 2321.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Bacher, T. Haferlach, C. Schoch, W. Kern, and S. Schnittger
Implications of NRAS mutations in AML: a study of 2502 patients
Blood,
May 15, 2006;
107(10):
3847 - 3853.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. J. Jabbour, E. Estey, and H. M. Kantarjian
Adult Acute Myeloid Leukemia
Mayo Clin. Proc.,
February 1, 2006;
81(2):
247 - 260.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Schnittger, C. Schoch, W. Kern, C. Mecucci, C. Tschulik, M. F. Martelli, T. Haferlach, W. Hiddemann, and B. Falini
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype
Blood,
December 1, 2005;
106(12):
3733 - 3739.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Growney, H. Shigematsu, Z. Li, B. H. Lee, J. Adelsperger, R. Rowan, D. P. Curley, J. L. Kutok, K. Akashi, I. R. Williams, et al.
Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype
Blood,
July 15, 2005;
106(2):
494 - 504.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
